Immunotoxicological Concerns for Vaccines and Adjuvants

Immunotoxicology Strategies for Pharmaceutical Safety Assessment

Volumn , Issue , 2008, Pages 229-237

  Kaplanski, Catherine ^a   Lebron, Jose ^a   Wolf, Jayanthi ^a   Ledwith, Brian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adjuvants and vaccines in systemic inflammatory response risk; Antigen selection and oncofetal antigen carcinoembryonic antigen (CEA); Therapeutic cancer vaccine and autoimmunity risk

Indexed keywords

EID: 79961113287     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470386385.ch18     Document Type: Chapter

References (43)

1. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T -lymphocyte antigen-4. J Clin Oncol 2005;23:6043-6053.
2. Brown ME, DaSilva KA, McLaurin J. Refining an Alzheimer's vaccine to avoid an inflammatory response. Expert Opin Biol Ther 2005;5:809-816.
3. Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF. Safety and immunogenicity of a DNA vaccine encoding carcino -embryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002;8:2782-2787.
4. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG. Adjuvant -dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003;15:505-514.
5. Danet-Desnoyers GA, Luongo JL, Bonnet DA, Domchek SM, Vonderheide RH. Telomerase vaccination has no detectable effect on SCID-repopulating and colony -forming activities in the bone marrow of cancer patients. Exp Hematol 2005;33:1275-1280.
6. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T cell immunity to the HER-2/neu protein after active immunization with a HER-2/neu peptide-based vaccine. J Clin Oncol 2002;20:2624-2632.
7. Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. Effect of dose on immune response in patients vaccinated with a HER-2/neu intracellular domain protein based vaccine. J Clin Oncol 2004;22:1916-1925.
8. Eades-Perner AM, Zimmermann W. Carcinoembryonic antigen-transgenic mice:a model for tumor immunotherapy. Tumour Biol 1995;16:56-61.
9. Egilmez NK. Cytokines as vaccine adjuvants. In:Vaccine Adjuvants and Delivery Systems, edited by Singh M, pp. 327-354. Hoboken, NJ:John Wiley & Sons, 2007.
10. EMEA. Note for guidance on the pharmacological and toxicological testing of vaccines. CPMP/SWP/465/95, 1997.
11. EMEA. Guideline on adjuvants in vaccines for human use. EMEA/CPMP/VEG/ 134716/2004, 2005.
12. EMEA. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07, 2007.
13. Frolkis M, Fischer MB, Wang Z, Lebkowski JS, Chiu CP, Majumdar AS. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors. Cancer Gene Ther 2003;10:239-249.
14. Gilboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2001;2:789-792.
15. Grubeck-Loebenstein B, Blasko I, Marx FK, Trieb I. Immunization with beta amyloid:could T-cell activation have a harmful effect? Trends Neurosci 2000;23:114.
16. Hörig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW, Schlom J, Kaufman HL. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49:504-514.
17. Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, Kung HF, Lin MC. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol 2006;3:1-11.
18. ICH (International Conference on Harmonization). Guidance for Industry. S8 Immunotoxicity Studies for Human Pharmaceuticals, 2006.
19. Johnson DA, Baldridge JR. TLR4 agonists as vaccine adjuvants. In:Vaccine Adjuvants and Delivery Systems, edited by Singh M, pp. 131-156. Hoboken, NJ:John Wiley & Sons, 2007.
20. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-683.
21. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T cell immunity in cancer patients. J Clin Invest 2001;107:477-484.
22. Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ. Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev Vaccines 2005;4:855-866.
23. Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ. Nonclinical safety assessment of vaccines and the evaluation of novel adjuvants and delivery systems. In:Vaccine Adjuvants and Delivery Systems, edited by Singh M, pp. 403-420. Hoboken, NJ:John Wiley & Sons, 2007.
24. Lindblad EB. Safety evaluation of vaccine adjuvants. In:Vaccine Adjuvants and Delivery Systems, edited by Singh M, pp. 421-444. Hoboken, NJ:John Wiley & Sons, 2007.
25. Ludewing B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000;191:795-803.
26. Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA. Short amyloid -beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006;26:4717-4728.
27. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J. P hase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-3973.
28. McMillian M, Kong LY, Sawin SM, Wilson B, Das K, Hudson P, Hong JS, Bing GY. Selective killing of cholinergic neurons by microglial activation in basal forebrain mixed neuronal/glial cultures. Biochem Biophys Res Commun 1995;215:572-577.
29. Münch G, Robinson SR. Potential neurotoxic inflammatory responses to A ß vaccination in humans. J Neural Transm 2002;109:1081-1087.
30. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan C, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a " self " antigen induces autoimmune vitiligo and tumor cell destruction in mice:requirement for CD4 + T lymphocytes. Proc Natl Acad Sci USA 1999;96:2982-2987.
31. Portielje J, Kruit W, Eerenberg A, Schuler M, Sparreboom A, Lamers C. Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans:implications for the use of IL-12 as vaccine adjuvant. Cancer Immunol Immunother 2005;54:37-43.
32. Pride MW, Black RS, Hagen M, Dispoto S, Souza V, Giorgio D, Zhao X, Jenkins L, Johnson-Fenno L, Ginsberg R, Daniels M, Koller M, Eldridge J. Evaluation of potential immunologic mechanisms in the pathogenesis of treatment-induced meningoencephalitis in Alzheimer's disease patients treated with AN1792 (QS-21). Neurobiol Aging 2004;25:S574.
33. Rodriguez-Lecompte JC, Kruth S, Gyorffy S, Wan Y, Gauldie J. Cell-based cancer gene therapy:breaking tolerance or inducing autoimmunity? Anim Health Res Rev 2004;5:227-234.
34. Schenk D. Amyloid-ß immunotherapy for Alzheimer's disease:the end of the beginning. Nat Rev Neurosci 2002;3:824-828.
35. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-ß attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
36. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004;16:599-606.
37. Shay JW, Wright WE. Telomerase:a target for cancer therapeutics. Cancer Cell 2002;2:257-265.
38. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, Vieweg J. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8 + and CD4 + T cell responses in patients with metastatic prostate cancer. J Immunol 2005;174:3798-3807.
39. Tabi Z, Man S. Challenges for cancer vaccine development. Adv Drug Deliv Rev 2006;58:902-915.
40. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/ macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-366.
41. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004;10:828-839.
42. WHO. Guidelines on Nonclinical Evaluation of Vaccines. WHO/BS/03.1969, 2003.
43. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry:protein antigens. Clin Cancer Res 1998;4:2669-2676.